Kane Biotech Inc.
KNBIF
$0.02
$0.00-8.08%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -345.16% | -69.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -345.16% | -69.31% | |||
| Cost of Revenue | -308.08% | -81.36% | |||
| Gross Profit | 245.95% | 88.75% | |||
| SG&A Expenses | 36.23% | 172.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.91% | 82.72% | |||
| Operating Income | -14.42% | -98.19% | |||
| Income Before Tax | -6.51% | -75.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.04% | -75.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.04% | -75.07% | |||
| EBIT | -14.42% | -98.19% | |||
| EBITDA | -36.04% | -95.53% | |||
| EPS Basic | -69.23% | 13.33% | |||
| Normalized Basic EPS | -100.00% | 20.00% | |||
| EPS Diluted | -223.08% | 13.33% | |||
| Normalized Diluted EPS | -100.00% | 11.11% | |||
| Average Basic Shares Outstanding | -46.46% | 108.04% | |||
| Average Diluted Shares Outstanding | -46.46% | 87.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||